Targeted Oncology | NSCLC Case Study
Targeted Oncology | Dialogues in Diagnostics
Targeted Oncology | Differential Diagnosis
Targeted Oncology | Case-Base Peer-Perspective

Top Medical News Today

Novel Therapies Set to Revolutionize Glioma Treatment
Targeted Oncology spoke with Andrew S. Chi, MD, PhD, head of Neuro-Oncology at NYU Langone's Laura and Isaac Perlmutter Cancer Center, on recent developments in the treatment paradigm for patients with brain cancer, including his recent study into mutant IDH1 gliomas and the role of the NAD metabolite.
Nicholas A. Butowski, MD, director, Translational Research in Neuro-Oncology, University of California, San Francisco, discusses the eligibility of patients with glioblastoma to receive a convection-enhanced delivery of nanoliposomal irinotecan with real-time imaging.
​Rimas Lukas, MD, director, Medical Neuro-Oncology, co-director, Neurology Medical Student Clerkship Program, The University of Chicago Medical Center, discusses the next steps following a phase I study looking at atezolizumab in glioblastoma.
The FDA has granted sacituzumab govitecan (IMMU-132) breakthrough therapy designation for the treatment of patients with triple-negative breast cancer (TNBC) following at least 2 treatments for metastatic disease, according to Immunomedics, the manufacturer of the investigational antibody-drug conjugate.
Adjuvant chemotherapy was associated with improved overall survival (OS) compared with observation postcystectomy in patients with pathologic T3/4 and/or pathologic node-positive bladder cancer, according to a retrospective analysis published in the Journal of Clinical Oncology.
Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the targeted, systemic radiation treatment 177-Lu-Dotatate (Lutathera), a somatostatin analogue peptide, in patients with neuroendocrine tumors.
Oliver Sartor, MD, medical director, Tulane Cancer Center, discusses how radium-223 dichloride became deemed safe in patients with bone-metastatic castration-resistant prostate cancer (CRPC). The treatment was tested in an open-label phase I/II trial where patients were given 6 additional doses of radium-223 on top of their original 6-dose regimen.
Carey Anders, MD, assistant professor for the Department of Medicine, Division of Hematology and Oncology, UNC Chapel Hill, discusses the exclusion of patients with breast cancer who have developed brain metastases from clinical trials.
View More >


Evolving Paradigms
Evolving Paradigms
Triple Negative Breast Cancer
Engineered T Cells for Leukemia: A Review of Current Approaches and Applications
This review addresses the basics of CAR T-cell design and reviews data from published clinical studies in leukemia. It also contains commentary on the prospects of this promising new therapeutic strategy.
Hypertension Risk Among Cancer Patients Treated With Sunitinib: A Meta-analysis and Systematic Review
Sunitinib treatment is associated with a significantly increased risk of all-grade and high-grade hypertension.
Evolving Paradigms: Gynecologic Cancer
In the past decade, there has been a rapid increase in the understanding of how various cancers develop and progress, which has led to the advance of novel and more targeted strategies for the prevention, diagnosis, and treatment of many malignancies.
Special Report on Gastrointestinal Cancers
A collection of articles and videos focused on the most recent clinical advances for patients with gastrointestinal cancers.
Updates on New and Emerging Therapies for Neuroendocrine Tumors
This case-based program is designed to educate medical oncologists, surgical oncologists, radiation oncologists, hem-oncs, and other allied health professionals on updates on new and emerging therapies for neuroendocrine tumors.